October 15, 2025 - 21:37

Akamai Technologies' Chief Information Officer, Kate Prouty, has observed a growing enthusiasm among the company's workforce regarding artificial intelligence. Employees are eager to explore the potential applications of AI, reflecting a strong curiosity and desire to leverage this technology in their daily tasks. However, Prouty remains cautious, expressing reservations about the actual benefits that AI may deliver.
While the excitement surrounding AI is palpable, Prouty emphasizes the importance of a balanced approach. She acknowledges the transformative potential of AI but also highlights the need for careful consideration of its implications. Concerns about the reliability, ethical usage, and long-term impact of AI technologies loom large in her mind.
As organizations increasingly integrate AI into their operations, Prouty advocates for a thorough evaluation of its capabilities and limitations. Striking a balance between enthusiasm and skepticism will be crucial as the company navigates the evolving landscape of artificial intelligence.
August 9, 2026 - 18:31
County agenda features tax, technology and fairgroundsThe meeting will center on how to fund the ongoing fairgrounds project, a long-discussed priority for the county. Officials are expected to review the latest cost estimates and possible revenue...
August 9, 2026 - 00:24
‘AI slop’ crackdown: LinkedIn, Snap target low-quality gen-AI contentSocial platforms are starting to push back against the flood of generic, machine-generated posts, but they are doing so carefully. LinkedIn and Snap have both announced new measures aimed at...
August 8, 2026 - 05:47
Why GigaCloud Technology (GCT) Is Up 21.7% After Strong Q2 Results And New Buyback PlanGigaCloud Technology saw its stock surge 21.7% in early trading following the release of its second-quarter financial results and the announcement of a new capital return program. The company...
August 7, 2026 - 22:40
As FDA Approves First-Ever mRNA Flu Vaccine For Older Adults, Past KFF Polling Showed Most In This Age Group Were Uncertain About the Technology’s SafetyOn August 5, 2026, the U.S. Food and Drug Administration gave the green light to the first messenger RNA flu vaccine for adults aged 50 and older. The decision came after a clinical trial involving...